CoChat

The Src-Family Kinase Inhibitor PP2 Rescues Inducible Differentiation Events in Emergent Retinoic Acid-Resistant Myeloblastic Leukemia Cells

Open access

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Abstract

Retinoic acid is an embryonic morphogen and dietary factor that demonstrates chemotherapeutic efficacy in inducing maturation in leukemia cells. Using HL60 model human myeloid leukemia cells, where all-trans retinoic acid (RA) induces granulocytic differentiation, we developed two emergent RA-resistant HL60 cell lines which are characterized by loss of RA-inducible G1/G0 arrest, CD11b expression, inducible oxidative metabolism and p47(phox) expression. However, RA-treated RA-resistant HL60 continue to exhibit sustained MEK/ERK activation, and one of the two sequentially emergent resistant lines retains RA-inducible CD38 expression. Other signaling events that define the wild-type (WT) response are compromised, including c-Raf phosphorylation and increased expression of c-Cbl, Vav1, and the Src-family kinases (SFKs) Lyn and Fgr. As shown previously in WT HL60 cells, we found that the SFK inhibitor PP2 significantly increases G1/G0 cell cycle arrest, CD38 and CD11b expression, c-Raf phosphorylation and expression of the aforementioned regulators in RA-resistant HL60. The resistant cells were potentially incapable of developing inducible oxidative metabolism. These results motivate the concept that RA resistance can occur in steps, wherein growth arrest and other differentiation events may be recovered in both emergent lines. Investigating the mechanistic anomalies in resistant cell lines is of therapeutic significance and helps to mechanistically understand the response to retinoic acid's biological effects in WT HL60 cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0058621

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 48 h PE fluorescence (CD38 surface expression) histograms for RA-resistant HL60 cells over 84 days. RA-resistant HL60 cells were labeled with PE-conjugated anti-CD38 and analyzed by flow cytometry. RA-resistant HL60 grown continuously in RA initially display elevated CD38 expression (histogram located in the gate P2). A growing subpopulation that does not express CD38, despite continual RA exposure, is indicated (by an arrow) as a low signal peak (top left graph). Over the course of 84 days, the number of cells that do not express CD38 continues to increase. The two distinct RA-resistant HL60 cells lines (bottom right graph), one with RA-inducible CD38 expression and one that has lost RA-inducible CD38 expression, were separated using Fluorescent Activated Cell Sorting (FACS) and the separated cell lines were termed R38+ and R38−, respectively.
Figure 1 48 h PE fluorescence (CD38 surface expression) histograms for RA-resistant HL60 cells over 84 days. RA-resistant HL60 cells were labeled with PE-conjugated anti-CD38 and analyzed by flow cytometry. RA-resistant HL60 grown continuously in RA initially display elevated CD38 expression (histogram located in the gate P2). A growing subpopulation that does not express CD38, despite continual RA exposure, is indicated (by an arrow) as a low signal peak (top left graph). Over the course of 84 days, the number of cells that do not express CD38 continues to increase. The two distinct RA-resistant HL60 cells lines (bottom right graph), one with RA-inducible CD38 expression and one that has lost RA-inducible CD38 expression, were separated using Fluorescent Activated Cell Sorting (FACS) and the separated cell lines were termed R38+ and R38−, respectively.CC BY · PubMed Central
Figure 2 CD38 and CD11b expression, cell cycle progression, inducible ROS production and p47phox expression in control and RA-treated WT, R38+ and R38− HL60 cells. Error bars represent standard error of at least three repeats. P values were calculated using a student’s t test and are compared between untreated respective control unless otherwise indicated. A: Control and RA-treated WT, R38+ and R38− HL60 cells were labeled with PE-conjugated CD38 and APC-conjugated CD11b and analyzed by flow cytometry. To measure the percent positive signal, WT control was set to exclude 95% of the live cell population peak. RA-treated WT HL60 displayed significant (p<<0.001) increased CD38 (∼98%) and CD11b (∼45%) protein surface expression after 48 h. RA-treated R38+ also significantly (p<<0.001) upregulated CD38 (∼98%) surface expression at 48 h. However, neither RA-treated R38+ nor R38− displayed any significant upregulation of CD11b at 48 h. B: To assess cell cycle progression, control and RA-treated WT, R38+ and R38− HL60 cells were stained with propidium iodide-hypotonic solution and analyzed by flow cytometry. Controls were gated to approximately 45% G1/G0 phase, 35% S phase and 20% G2/M phase. RA-treated WT HL60 cells exhibited significant (p<0.01) increased G1/G0 arrest (∼60%) after 48 h. However, neither RA-treated R38+ nor R38− exhibited any increased G1/G0 growth arrest at 48 h. C: To assess ROS production, control and RA-treated WT, R38+ and R38− HL60 cells were stimulated with TPA and analyzed by NBT reduction. At 48 h and 72 h, only RA-treated WT HL60 cells displayed a significant ROS response (p<0.01 compared to both control and RA-treated resistant cells) after TPA induction. Neither RA-treated R38+ nor R38− was able to exhibit ROS production after stimulation with TPA at either 48 or 72 h. D: RA-treated WT HL60 cells showed enhanced p47phox expression after 48 h, whereas only minimal p47phox expression is induced by RA in R38+ and R38−.
Figure 2 CD38 and CD11b expression, cell cycle progression, inducible ROS production and p47phox expression in control and RA-treated WT, R38+ and R38− HL60 cells. Error bars represent standard error of at least three repeats. P values were calculated using a student’s t test and are compared between untreated respective control unless otherwise indicated. A: Control and RA-treated WT, R38+ and R38− HL60 cells were labeled with PE-conjugated CD38 and APC-conjugated CD11b and analyzed by flow cytometry. To measure the percent positive signal, WT control was set to exclude 95% of the live cell population peak. RA-treated WT HL60 displayed significant (p<<0.001) increased CD38 (∼98%) and CD11b (∼45%) protein surface expression after 48 h. RA-treated R38+ also significantly (p<<0.001) upregulated CD38 (∼98%) surface expression at 48 h. However, neither RA-treated R38+ nor R38− displayed any significant upregulation of CD11b at 48 h. B: To assess cell cycle progression, control and RA-treated WT, R38+ and R38− HL60 cells were stained with propidium iodide-hypotonic solution and analyzed by flow cytometry. Controls were gated to approximately 45% G1/G0 phase, 35% S phase and 20% G2/M phase. RA-treated WT HL60 cells exhibited significant (p<0.01) increased G1/G0 arrest (∼60%) after 48 h. However, neither RA-treated R38+ nor R38− exhibited any increased G1/G0 growth arrest at 48 h. C: To assess ROS production, control and RA-treated WT, R38+ and R38− HL60 cells were stimulated with TPA and analyzed by NBT reduction. At 48 h and 72 h, only RA-treated WT HL60 cells displayed a significant ROS response (p<0.01 compared to both control and RA-treated resistant cells) after TPA induction. Neither RA-treated R38+ nor R38− was able to exhibit ROS production after stimulation with TPA at either 48 or 72 h. D: RA-treated WT HL60 cells showed enhanced p47phox expression after 48 h, whereas only minimal p47phox expression is induced by RA in R38+ and R38−.CC BY · PubMed Central
Figure 3 48 h Western blot data for control and RA-treated WT, R38+ and R38− HL60 cells. A representative blot is displayed above its respective bar graph, and each bar graph (error bars represent standard error) presents the fold change respective to each control. The fold change was calculated after performing densitometry across three or more repeated blots. Note that the scale of the y-axis for each bar graph differs. A: There was no change in total ERK or MEK levels for any cell line. RA induced MEK and ERK phosphorylation in all three cell lines. Only RA-treated WT HL60 cells showed upregulation of c-Raf expression. Also, only RA-treated WT HL60 cells exhibited increased c-Raf phosphorylation at S259, S621 and S289/296/301. Neither R38+ nor R38− displayed increased c-Raf expression or phosphorylation after RA treatment. B: RA-treated WT HL60 cells showed upregulation of Lyn, Fgr, Vav1, and c-Cbl expression. RA-inducible Slp76 expression was evident in R38+ and R38−. Immunoprecipitation of c-Cbl followed by blotting of CD38 reveals that there is little CD38 and c-Cbl interaction in RA-treated R38+ compared to RA-induced WT HL60. GAPDH (not shown) served as loading control; c-Cbl (not shown) served as control for c-Cbl immunoprecipitation.
Figure 3 48 h Western blot data for control and RA-treated WT, R38+ and R38− HL60 cells. A representative blot is displayed above its respective bar graph, and each bar graph (error bars represent standard error) presents the fold change respective to each control. The fold change was calculated after performing densitometry across three or more repeated blots. Note that the scale of the y-axis for each bar graph differs. A: There was no change in total ERK or MEK levels for any cell line. RA induced MEK and ERK phosphorylation in all three cell lines. Only RA-treated WT HL60 cells showed upregulation of c-Raf expression. Also, only RA-treated WT HL60 cells exhibited increased c-Raf phosphorylation at S259, S621 and S289/296/301. Neither R38+ nor R38− displayed increased c-Raf expression or phosphorylation after RA treatment. B: RA-treated WT HL60 cells showed upregulation of Lyn, Fgr, Vav1, and c-Cbl expression. RA-inducible Slp76 expression was evident in R38+ and R38−. Immunoprecipitation of c-Cbl followed by blotting of CD38 reveals that there is little CD38 and c-Cbl interaction in RA-treated R38+ compared to RA-induced WT HL60. GAPDH (not shown) served as loading control; c-Cbl (not shown) served as control for c-Cbl immunoprecipitation.CC BY · PubMed Central
Figure 4 CD38 and CD11b expression, cell cycle progression, and p47phox expression in control, PP2- and/or RA-treated R38+ and R38− HL60 cells. Error bars represent standard error of at least three repeats. P values were calculated using a student’s t test and are compared between untreated respective control unless otherwise indicated. A: Control, RA-treated and/or PP2-treated R38+ and R38− HL60 cells were labeled with PE-conjugated CD38 and APC-conjugated CD11b and analyzed by flow cytometry. To measure the percent positive signal, controls were set to exclude 95% of the live cell population peak. After 48 h, PP2 induced significant (p<0.001) CD38 expression (∼50%) in R38+. Combined PP2+RA treatment in R38+ significantly increased (p<0.001) CD11b to levels comparable with those of RA-treated WT HL60 cells (∼40%). In R38−, co-treatment resulted in diminished yet still significant increases CD38 (p<0.05, nearly 40%) and CD11b (p<0.01, more than 20%) expression. PP2 treatment alone had no significant effect on CD38 or CD11b expression in R38−. B: To assess cell cycle progression, control and RA-treated WT, R38+ and R38− HL60 cells were stained with propidium iodide-hypotonic solution and analyzed by flow cytometry. Controls were gated to approximately 45% G1/G0 phase, 35% S phase and 20% G2/M phase. PP2 induced growth arrest (more than 60%) in both R38+ (p<0.01 alone and with RA) and R38− (p<0.01 with PP2 alone, p<0.05 with co-treatment). C: p47phox expression was upregulated in both R38+ and R38− with combined PP2+RA treatment. PP2 alone did not increase p47phox expression greater than RA treatment alone in either R38+ or R38−.
Figure 4 CD38 and CD11b expression, cell cycle progression, and p47phox expression in control, PP2- and/or RA-treated R38+ and R38− HL60 cells. Error bars represent standard error of at least three repeats. P values were calculated using a student’s t test and are compared between untreated respective control unless otherwise indicated. A: Control, RA-treated and/or PP2-treated R38+ and R38− HL60 cells were labeled with PE-conjugated CD38 and APC-conjugated CD11b and analyzed by flow cytometry. To measure the percent positive signal, controls were set to exclude 95% of the live cell population peak. After 48 h, PP2 induced significant (p<0.001) CD38 expression (∼50%) in R38+. Combined PP2+RA treatment in R38+ significantly increased (p<0.001) CD11b to levels comparable with those of RA-treated WT HL60 cells (∼40%). In R38−, co-treatment resulted in diminished yet still significant increases CD38 (p<0.05, nearly 40%) and CD11b (p<0.01, more than 20%) expression. PP2 treatment alone had no significant effect on CD38 or CD11b expression in R38−. B: To assess cell cycle progression, control and RA-treated WT, R38+ and R38− HL60 cells were stained with propidium iodide-hypotonic solution and analyzed by flow cytometry. Controls were gated to approximately 45% G1/G0 phase, 35% S phase and 20% G2/M phase. PP2 induced growth arrest (more than 60%) in both R38+ (p<0.01 alone and with RA) and R38− (p<0.01 with PP2 alone, p<0.05 with co-treatment). C: p47phox expression was upregulated in both R38+ and R38− with combined PP2+RA treatment. PP2 alone did not increase p47phox expression greater than RA treatment alone in either R38+ or R38−.CC BY · PubMed Central
Figure 5 48 h Western blot data for control, PP2, RA and PP2+RA treated R38+ and R38 −. A representative blot is displayed above its respective bar graph, and each bar graph (error bars represent standard error) presents the fold change respective to each control. The fold change was calculated after performing densitometry across three or more repeated blots. Note that the scale of the y-axis for each bar graph differs. A: There was no change in total ERK or MEK levels during any treatment for either R38+ or R38−. Interestingly, PP2 (alone and when co-treated with RA) decreased MEK and ERK phosphorylation in both R38+ and R38−. However PP2 and PP2+RA treatment induced upregulation of c-Raf expression and c-Raf phosphorylation at S259, S621 and S289/296/301 in both R38+ and R38−. B: PP2 and PP2+RA induced upregulation of Lyn, Vav1, c-Cbl and Slp76 expression. Y416 phosphorylation was reduced with PP2 treatment. C: Fgr can be detected with combined RA and PP2 treatment, but not with PP2 alone in both R38+ and R38−. Although the blots of Fgr were repeated three or more times, the blot that additionally displays the band for RA-treated WT HL60 (in the blot shown) was performed once. GAPDH (not shown) served as loading control.
Figure 5 48 h Western blot data for control, PP2, RA and PP2+RA treated R38+ and R38 −. A representative blot is displayed above its respective bar graph, and each bar graph (error bars represent standard error) presents the fold change respective to each control. The fold change was calculated after performing densitometry across three or more repeated blots. Note that the scale of the y-axis for each bar graph differs. A: There was no change in total ERK or MEK levels during any treatment for either R38+ or R38−. Interestingly, PP2 (alone and when co-treated with RA) decreased MEK and ERK phosphorylation in both R38+ and R38−. However PP2 and PP2+RA treatment induced upregulation of c-Raf expression and c-Raf phosphorylation at S259, S621 and S289/296/301 in both R38+ and R38−. B: PP2 and PP2+RA induced upregulation of Lyn, Vav1, c-Cbl and Slp76 expression. Y416 phosphorylation was reduced with PP2 treatment. C: Fgr can be detected with combined RA and PP2 treatment, but not with PP2 alone in both R38+ and R38−. Although the blots of Fgr were repeated three or more times, the blot that additionally displays the band for RA-treated WT HL60 (in the blot shown) was performed once. GAPDH (not shown) served as loading control.CC BY · PubMed Central
Figure 6 Wright’s stain cytology for control and treated WT, R38+ and R38− HL60 cell lines. Control WT cells are round; RA-treated R38+ and R38− also retain a round, stem-like appearance. WT HL60 cells showed morphological changes consistent with differentiation toward granulocytes when treated with RA, PP2, or PP2+RA. Meanwhile the two RA-resistant HL60 cell lines, R38+ and R38−, both showed morphological changes consistent with differentiation only during PP2 and PP2+RA treatment, but not RA treatment alone.
Figure 6 Wright’s stain cytology for control and treated WT, R38+ and R38− HL60 cell lines. Control WT cells are round; RA-treated R38+ and R38− also retain a round, stem-like appearance. WT HL60 cells showed morphological changes consistent with differentiation toward granulocytes when treated with RA, PP2, or PP2+RA. Meanwhile the two RA-resistant HL60 cell lines, R38+ and R38−, both showed morphological changes consistent with differentiation only during PP2 and PP2+RA treatment, but not RA treatment alone.CC BY · PubMed Central
Figure 7 Diagrams of the signaling proteins investigated in this study for each treatment case in R38+ and R38− compared to the RA-treated WT HL60 cells. For a given protein, solid black arrows indicate increased expression while white arrows indicate increased phosphorylation. Dashed black lines indicate an interaction that has previously been demonstrated in this lab by immunoprecipitation and/or FRET, with the exception of Fgr:Slp76 and Fgr:c-Raf. These two interactions are implied by the known binding of Slp76 and c-Raf to Src-family kinase members. Dashed black lines with arrowheads indicate phosphorylation (kinase) events known in the literature. Solid-filled factors vs. white-filled factors serve to clarify the expression indicated by the black arrows. Gradient-filled factors indicate expression but to a lower level than the RA-treated WT case. Downstream effects (CD11b expression, p47phox expression, etc) are written in black if they occur, grey if they do not occur, or in gradient if they occur but to a lesser extent than the RA-treated WT HL60 case. A: In RA-treated WT HL60, CD38 is upregulated, along with its intracellular binding partners Slp76, Vav1, c-Cbl, and Lyn. Fgr is also upregulated. MEK and ERK show increased phosphorylation, while c-Raf is upregulated and shows increased phosphorylation at S259, S621 and S289/296/301. Differentiation markers that occur include CD11b expression, cell cycle arrest, p47phox expression and inducible ROS production. B: In RA-treated R38+ HL60, CD38 is upregulated, but not Vav1, c-Cbl, or Lyn. Fgr is not upregulated. MEK and ERK show increased phosphorylation; however c-Raf is not upregulated, nor shows increased phosphorylation. Increased CD11b expression, cell cycle arrest, p47phox expression and inducible ROS production do not occur. C: In RA-treated R38− HL60, CD38 is not upregulated, nor Vav1, c-Cbl, or Lyn. Fgr is not upregulated. MEK and ERK show increased phosphorylation; however c-Raf is not upregulated, nor shows increased phosphorylation. Increased CD11b expression, cell cycle arrest, p47phox expression and inducible ROS production do not occur. D: In PP2-treated R38+ HL60, CD38 is partially upregulated (indicated by the gradient CD38), and Slp76, Vav1, c-Cbl, and Lyn are upregulated. Fgr is not upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Increased cell cycle arrest occurs, but not increased CD11b expression, p47phox expression or inducible ROS production. E: In PP2-treated R38− HL60, CD38 is not upregulated, but Slp76, Vav1, c-Cbl, and Lyn are upregulated. Fgr is not upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Increased cell cycle arrest occurs, but not increased CD11b expression, p47phox expression or inducible ROS production. F: In PP2+RA-treated R38+ HL60, CD38 is upregulated, along with Slp76, Vav1, c-Cbl, and Lyn. Fgr is also upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Differentiation markers that occur include CD11b expression, cell cycle arrest, and p47phox expression, but not inducible ROS production. G: In PP2+RA-treated R38− HL60, CD38 is partially upregulated, along with Slp76, Vav1, c-Cbl, and Lyn. Fgr is also upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Differentiation markers that occur include partial CD11b expression, cell cycle arrest, and p47phox expression, but not inducible ROS production.
Figure 7 Diagrams of the signaling proteins investigated in this study for each treatment case in R38+ and R38− compared to the RA-treated WT HL60 cells. For a given protein, solid black arrows indicate increased expression while white arrows indicate increased phosphorylation. Dashed black lines indicate an interaction that has previously been demonstrated in this lab by immunoprecipitation and/or FRET, with the exception of Fgr:Slp76 and Fgr:c-Raf. These two interactions are implied by the known binding of Slp76 and c-Raf to Src-family kinase members. Dashed black lines with arrowheads indicate phosphorylation (kinase) events known in the literature. Solid-filled factors vs. white-filled factors serve to clarify the expression indicated by the black arrows. Gradient-filled factors indicate expression but to a lower level than the RA-treated WT case. Downstream effects (CD11b expression, p47phox expression, etc) are written in black if they occur, grey if they do not occur, or in gradient if they occur but to a lesser extent than the RA-treated WT HL60 case. A: In RA-treated WT HL60, CD38 is upregulated, along with its intracellular binding partners Slp76, Vav1, c-Cbl, and Lyn. Fgr is also upregulated. MEK and ERK show increased phosphorylation, while c-Raf is upregulated and shows increased phosphorylation at S259, S621 and S289/296/301. Differentiation markers that occur include CD11b expression, cell cycle arrest, p47phox expression and inducible ROS production. B: In RA-treated R38+ HL60, CD38 is upregulated, but not Vav1, c-Cbl, or Lyn. Fgr is not upregulated. MEK and ERK show increased phosphorylation; however c-Raf is not upregulated, nor shows increased phosphorylation. Increased CD11b expression, cell cycle arrest, p47phox expression and inducible ROS production do not occur. C: In RA-treated R38− HL60, CD38 is not upregulated, nor Vav1, c-Cbl, or Lyn. Fgr is not upregulated. MEK and ERK show increased phosphorylation; however c-Raf is not upregulated, nor shows increased phosphorylation. Increased CD11b expression, cell cycle arrest, p47phox expression and inducible ROS production do not occur. D: In PP2-treated R38+ HL60, CD38 is partially upregulated (indicated by the gradient CD38), and Slp76, Vav1, c-Cbl, and Lyn are upregulated. Fgr is not upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Increased cell cycle arrest occurs, but not increased CD11b expression, p47phox expression or inducible ROS production. E: In PP2-treated R38− HL60, CD38 is not upregulated, but Slp76, Vav1, c-Cbl, and Lyn are upregulated. Fgr is not upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Increased cell cycle arrest occurs, but not increased CD11b expression, p47phox expression or inducible ROS production. F: In PP2+RA-treated R38+ HL60, CD38 is upregulated, along with Slp76, Vav1, c-Cbl, and Lyn. Fgr is also upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Differentiation markers that occur include CD11b expression, cell cycle arrest, and p47phox expression, but not inducible ROS production. G: In PP2+RA-treated R38− HL60, CD38 is partially upregulated, along with Slp76, Vav1, c-Cbl, and Lyn. Fgr is also upregulated. MEK and ERK phosphorylation is decreased; however c-Raf is upregulated and shows increased phosphorylation. Differentiation markers that occur include partial CD11b expression, cell cycle arrest, and p47phox expression, but not inducible ROS production.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 18

Metadata

Authors
Jensen, H. A., Styskal, L. E., Tasseff, R., Bunaciu, R. P., Congleton, J., Varner, J. D., & Yen, A.
Affiliations
Cornell University (US)
Corresponding author
Yen, Andrew
Venue
PLoS ONE
Published
2013-03-15
Volume
8
Issue
3
Pages
e58621
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1995083340
Cited by
18
References
57
Citations by year
2025: 2 · 2020: 3 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 3
FWCI
1.19
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (0846876, CAREER)
  • New York State Department of Health
  • New York State Stem Cell Science
  • National Institutes of Health
  • National Cancer Institute (CA033505, CA152870, R01CA152870, R01CA033505)
  • Division of Chemical, Bioengineering, Environmental, and Transport Systems
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
Keywords
retinoic acid resistance, myeloblastic leukemia, HL-60 cells, PP2, Src family kinases, granulocytic differentiation, MEK/ERK signaling, CD38, CD11b, G1 cell cycle arrest, oxidative metabolism, p47phox, Vav1, c-Cbl, Fgr, Lyn kinase
MeSH terms
Antineoplastic Agents, Cell Differentiation, Humans, Leukemia, Myeloid, Membrane Glycoproteins, Proto-Oncogene Proteins, Pyrimidines, Tretinoin, Gene Expression Regulation, Leukemic, Resting Phase, Cell Cycle, HL-60 Cells, Drug Resistance, Neoplasm, src-Family Kinases, NADPH Oxidases, CD11b Antigen, Proto-Oncogene Proteins c-cbl, Proto-Oncogene Proteins c-vav, ADP-ribosyl Cyclase 1, G1 Phase Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Src-Family Kinase Inhibitor PP2 Rescues Inducible Differentiation Events in Emergent Retinoic Acid-Resistant Myeloblastic Leukemia Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0058621
The paper
Jensen, H. A., Styskal, L. E., Tasseff, R., Bunaciu, R. P., Congleton, J., Varner, J. D., & Yen, A. (2013). The Src-Family Kinase Inhibitor PP2 Rescues Inducible Differentiation Events in Emergent Retinoic Acid-Resistant Myeloblastic Leukemia Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0058621

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.